

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>SCP Vitalife Partners II LP</u> (Last) (First) (Middle) 7 GREAT VALLEY PARKWAY SUITE 109 (Street) MALVERN PA 19355-1446 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ReWalk Robotics Ltd. [RWLK]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/19/2016	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares, par value NIS 0.01 per share	05/19/2016		S		3,748	D	\$9.119 ⁽¹⁾	1,210,328	D ⁽²⁾	
Ordinary Shares, par value NIS 0.01 per share	05/20/2016		S		8,357	D	\$9.0788 ⁽³⁾	1,201,971	D ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)					

1. Name and Address of Reporting Person*
SCP Vitalife Partners II LP
 (Last) (First) (Middle)
 7 GREAT VALLEY PARKWAY
 SUITE 109
 (Street)
 MALVERN PA 19355-1446
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SCP Vitalife II Associates, L.P.
 (Last) (First) (Middle)
 7 GREAT VALLEY PARKWAY
 SUITE 109
 (Street)
 MALVERN PA 19355-1446
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SCP Vitalife II GP, Ltd.

(Last)	(First)	(Middle)
<u>7 GREAT VALLEY PARKWAY</u>		
<u>SUITE 109</u>		
<hr/>		
(Street)		
<u>MALVERN</u>	<u>PA</u>	<u>19355-1446</u>
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*

CHURCHILL WINSTON J

(Last)	(First)	(Middle)
<u>7 GREAT VALLEY PARKWAY</u>		
<u>SUITE 109</u>		
<hr/>		
(Street)		
<u>MALVERN</u>	<u>PA</u>	<u>19355-1446</u>
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*

LUDOMIRSKI ABRAHAM

(Last)	(First)	(Middle)
<u>7 GREAT VALLEY PARKWAY</u>		
<u>SUITE 109</u>		
<hr/>		
(Street)		
<u>MALVERN</u>	<u>PA</u>	<u>19355-1446</u>
<hr/>		
(City)	(State)	(Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.0800 to \$9.1900, inclusive. The reporting person undertakes to provide to ReWalk Robotics Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
2. The Ordinary Shares are directly held by SCP Vitalife Partners II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.0000 to \$9.2800, inclusive. The reporting person undertakes to provide to ReWalk, any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

/s/ Winston J. Churchill,
attorney-in-fact

05/23/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.